We are live on
!
Find out more
LCP
Lamond Capital Partners Portfolio holdings
AUM
$14.3M
1-Year Est. Return
30.74%
This Fund
S&P 500
This Quarter
Est. Return
+7.65%
1 Year Est. Return
-30.74%
3 Year Est. Return
+54.28%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$66.9M
AUM Growth
-$66.7M
(-50%)
Cap. Flow
-$68.7M
Cap. Flow
% of AUM
-102.61%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
16
New
6
Increased
–
Reduced
1
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oracle
ORCL
|
+$19.1M |
| 2 |
Puma Biotechnology
PBYI
|
+$17.3M |
| 3 |
AbbVie
ABBV
|
+$17.3M |
| 4 |
RXDX
Ignyta, Inc.
RXDX
|
+$563K |
| 5 |
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
|
+$509K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ocular Therapeutix
OCUL
|
+$17.3M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$15.6M |
| 3 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$11M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$10.5M |
| 5 |
CY
Cypress Semiconductor
CY
|
+$9.37M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 72.24% |
| 2 | Technology | 27.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Oracle
ORCL
$331B
| $18.3M | 27.3% |
+500,000
| New | +$19.1M |
|
|
2
AbbVie
ABBV
$458B
| $17.8M | 26.56% |
+300,000
| New | +$17.3M |
|
|
3
Puma Biotechnology
PBYI
$406M
| $17.3M | 25.87% |
+220,780
| New | +$17.3M |
|
4
Amgen
AMGN
$203B
| $12.2M | 18.2% |
75,000
-25,000
| -25% | -$3.93M |
|
|
RXDX
5
DELISTED
Ignyta, Inc.
RXDX
| $626K | 0.94% |
+46,721
| New | +$563K |
|
|
ZLTQ
6
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
| $460K | 0.69% |
+16,119
| New | +$509K |
|
|
IMMU
7
DELISTED
Immunomedics Inc
IMMU
| $307K | 0.46% |
+100,000
| New | +$279K |
|
|
8
CALL
AbbVie
ABBV
$458B
| – | – |
-250,000
| Closed | -$13.6M |
|
|
9
CALL
Amgen
AMGN
$203B
| – | – |
-150,000
| Closed | -$20.7M |
|
|
10
BioMarin Pharmaceuticals
BMRN
$11.5B
| – | – |
-100,000
| Closed | -$10.5M |
|
|
11
Ocular Therapeutix
OCUL
$1.86B
| – | – |
-1,233,285
| Closed | -$17.3M |
|
|
12
CALL
Oracle
ORCL
$331B
| – | – |
-500,000
| Closed | -$18.1M |
|
|
ALXN
13
DELISTED
Alexion Pharmaceuticals
ALXN
| – | – |
-100,000
| Closed | -$15.6M |
|
|
GWPH
14
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| – | – |
-120,000
| Closed | -$11M |
|
|
KITE
15
CALL
DELISTED
Kite Pharma, Inc.
KITE
| – | – |
-63,400
| Closed | -$3.53M |
|
|
CY
16
DELISTED
Cypress Semiconductor
CY
| – | – |
-1,100,000
| Closed | -$9.37M |
|
Similar funds
HCM
PPF
PM
TSU
RCMC
SCA
GFWEV
STA
Lamond Capital Partners's Q4 2015 Portfolio in Review
As of Q4 2015, Lamond Capital Partners held 16 positions worth $66.9M, down 50% from $134M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Lamond Capital Partners withdrew a net $68.7M in Q4 2015, closing 9 positions and reducing 1 holding. Its most notable exit was Ocular Therapeutix, an estimated $17.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 51% a quarter earlier, followed by Technology.
Against the trend, Lamond Capital Partners opened a new position in Oracle worth $18.3M.
- Lamond Capital Partners's largest Q4 2015 buy was Oracle: 500,000 shares worth $18.3M.
- Lamond Capital Partners's biggest Q4 2015 reduction was Amgen, cutting an estimated $3.93M.
- Lamond Capital Partners fully exited Ocular Therapeutix in Q4 2015, selling an estimated $17.3M.
- Lamond Capital Partners's ten largest holdings make up 100% of its $66.9M portfolio in Q4 2015.
- Lamond Capital Partners opened 6 new positions and closed 9 in Q4 2015.
- Lamond Capital Partners's portfolio value fell 50% quarter-over-quarter to $66.9M.
Based on Lamond Capital Partners's 13F filing for Q4 2015, filed 9 Feb 2016.